Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium

Girolamo Pelaia¹*, Rosario Maselli¹ and Luca Gallelli²

Abstract

Chronic obstructive pulmonary disease (COPD) is a widespread respiratory disorder, usually characterized by progressive and poorly reversible airflow limitation. Inhaled long-acting bronchodilators, namely LABA (long-acting β₂-adrenergic agonists) and LAMA (long-acting muscarinic receptor antagonists) are the mainstay of COPD treatment. Because the symptoms of many patients with COPD do not satisfactorily improve by using a single, either LABA or LAMA bronchodilator, the synergism of action resulting from the combination of the different bronchodilating mechanisms activated by LABA and LAMA, respectively, can significantly contribute to a better disease control. Based on these clinical and pharmacological considerations, several LABA/LAMA fixed-dose combinations have been developed and experimentally evaluated. Within such a context, the drug co-formulation containing indacaterol and glycopyrronium is probably the LABA/LAMA association which has been most extensively studied during the last few years.

Keywords: Co-formulation, Dual bronchodilation, Glycopyrronium, Indacaterol, LABA, LAMA, Synergism, QVA149

Introduction

COPD is characterized by a barely reversible airflow limitation, thus it is easily understandable that inhaled bronchodilators such as LABA and LAMA are the main pharmacological options in order to improve lung function, dyspnea, exercise tolerance and overall quality of life, as well as to prevent disease exacerbations [1]. Moreover, current guidelines recommend the combined use of LABA and LAMA when symptoms are not adequately improved by a single bronchodilator [2]. The rationale of using these two drug classes is based on their ability to effectively interfere with the bronchoconstrictive signaling network leading to the respiratory dysfunction underlying COPD. In particular, by means of different mechanisms of action, LABA and LAMA can counteract the increased bronchomotor tone, which in COPD patients is mainly sustained by an excessive activation of cholinergic pathways. Therefore, LABA and LAMA act cooperatively by reciprocally potentiating their bronchodilating effects [3]. These positive pharmacological interactions can be further amplified by the different distribution patterns of receptor targets throughout the bronchial tree. Indeed, bronchodilating β₂-adrenergic receptors (β₂-ARs) are located along all the respiratory system, but their density progressively increases from the proximal, larger airways towards the distal, smaller ones. Vagal cholinergic innervation is mostly distributed within the central airways, where bronchoconstrictive muscarinic receptors are present in higher numbers; however, extra-neuronal acetylcholine (ACh) mainly activates muscarinic receptors placed in peripheral airways [4]. Among LABA/LAMA combinations, a remarkable amount of pharmacological and clinical information has been obtained by evaluating the effects of the fixed-dose co-formulation of indacaterol and glycopyrronium, known as QVA149 [5]. Indacaterol is a LABA used once daily, as it provides a prolonged bronchodilation, lasting at least 24 hours [6,7]. Glycopyrronium (NVA237) is a recently developed LAMA that, similarly to indacaterol, induces a persistent, 24 hour-long bronchodilation, thus being also suitable for once daily administration [8,9]. Therefore, by acting via
their distinct mechanisms of action, when used together indacaterol and glycopyrronium can exert synergistic effects, thereby optimizing and maximizing bronchodilation in those COPD patients whose needs are not adequately met by a monotherapy performed with a single bronchodilator.

The aim of this review article is firstly to outline the mechanisms of action of QVA149, and then discuss its clinical and functional effects, as well as the safety and tolerability profile.

**Review**

**Basic mechanisms of action**

All $\beta_2$-adrenergic receptor ($\beta_2$-AR) agonists, also including indacaterol, relax airway smooth muscle (ASM) regardless of the nature and multitude of bronchoconstrictive stimuli, thus acting as functional antagonists of bronchoconstriction. In particular, these drugs activate $\beta_2$-ARs, which are coupled to the stimulatory G protein (Gs) that is, in turn, responsible for the stimulation of adenyl cyclase (AC) and the subsequent increase in the concentration of intracellular second messenger cyclic adenosine 3’5’-monophosphate (cAMP) (Figure 1) [10]. The latter activates cAMP-dependent protein kinase A (PKA), which phosphorylates several targets within the cell, thereby leading to inhibition of Ca$^{2+}$-dependent ASM contraction [11]. Indacaterol is a powerful $\beta_2$-adrenergic agonist, being able to induce a very fast and prolonged bronchodilation, which lasts for approximately 24 hours [12]. This drug has an intense intrinsic activity at the level of $\beta_2$-ARs, and its bronchodilating action does not elicit significant tachyphylaxis. Unlike salmeterol, indacaterol does not alter the fluidity of cell membrane, and its long-lasting bronchodilating effect is due to a high affinity of the lipophilic tail of the molecule for the so-called “lipid rafts” [13]. These consist of micro-domains rich in cholesterol and sphingolipids, that, within the cell membrane, function as aggregation sites for $\beta_2$-ARs, thus also facilitating their connection with the signaling pathway including Gs and AC. The rapid onset of the bronchodilating action of indacaterol depends on its hydrophilic head, which interacts with the $\beta_2$-AR hydrophilic pocket surrounded by the seven hydrophobic transmembrane domains of this G protein-coupled receptor.

The bronchoconstrictive effect of ACh can be inhibited by inhaled anticholinergic drugs, which act through a competitive antagonism of muscarinic receptors. Glycopyrronium bromide is a powerful once-daily inhaled anticholinergic agent, characterized by a high kinetic selectivity for $M_3$ versus $M_2$ muscarinic receptors (Figure 1) [14,15]. Therefore, glycopyrronium operates via a prolonged blockade of $M_3$ receptors, whereas this drug rapidly dissociates from $M_2$ receptors. With regard to airway muscarinic receptors, this kinetic pattern of glycopyrronium is very relevant, in that ACh-dependent ASM contraction is mainly mediated by $M_3$ receptors, whilst $M_2$ receptors are primarily responsible for pre-junctional inhibition of ACh release from postganglionic vagal nerves [16,17]. Furthermore, cardiac $M_2$ receptors modulate atrial pacemaker activity, atrio-ventricular conduction and ventricular electro-mechanical coupling [18]. A persistent blockade of $M_2$ muscarinic receptors could thus attenuate bronchodilation primarily due to $M_3$ receptor antagonism, as well as increase the risk of unwanted
cardiovascular side effects, including tachycardia and arrhythmias. Therefore, by largely preserving M2 receptor functions, glycopyrronium maximizes bronchodilation and is also characterized by a very good pattern of cardiovascular safety [8,9].

The remarkable bronchodilating action of glycopyrronium is thus mainly mediated by a very effective prevention of the activation of M3 receptors, coupled to the Gq protein that, in turn, stimulates the β isof orm of phospholipase C (PLC-β), which cleaves phosphatidyl-inositol 4,5-bisphosphate (PIP2) into two intracellular second messengers: inositol 1,4,5-trisphosphate (IP3) and 1,2 diacylglycerol (DAG) [19]. IP3 activates its receptor localized in the sarcoplasm ric reticulum (SR), thereby releasing into the cytosol calcium ions (Ca2+) which bind to calmodulin, thus inducing the activation of myosin light chain kinase (MLCK). MLCK phosphorylates myosin light chain (MLC), thereby promoting the subsequent actin-myosin interaction, which is responsible for ASM contraction. The long-lasting bronchodilating effect of glycopyrronium is associated with a very fast onset of action, due to the rapid occupancy of muscarinic receptors. Such an immediate blockade of ASM M3 receptors is thus responsible for a prompt decrease in the concentration of cytosolic Ca2+ levels, paralleled by a rapid inhibition of bronchoconstriction elicited by cholinergic agents [15].

The advantageous bronchodilating pattern of glycopyrronium explains its excellent therapeutic profile, emerging from several clinical trials. In particular, the GLOW1 and GLOW2 studies showed that glycopyrronium provides a rapid and sustained FEV1 (forced expiratory volume in one second) increase, already detectable within 5 minutes of administration [9,20].

Clinical and functional effects

On the basis of the above discussed pharmacological concepts, several controlled trials have been carried out to evaluate the potential benefits of QVA149 in COPD treatment [5]. The positive results of such studies have led to the recent approval of this drug co-formulation in Europe, Canada and Japan [26-28]. All these trials have been performed using the Breezhaler® dry powder device, containing a capsule including 110 mcg of indacaterol and 50 mcg of glycopyrronium. The delivered dose, leaving the inhaler at the level of its mouthpiece, consists of 85 mcg of indacaterol and 43 mcg of glycopyrronium, respectively.

The double-blind, randomized and placebo-controlled trial called ENLIGHTEN was carried out for 52 weeks in 339 patients with moderate-to-severe COPD, who exhibited post-bronchodilator FEV1 measurements ranging from 30% to 80% of predicted values [29]. QVA149 significantly improved lung function, thus steadily increasing FEV1 throughout the whole study period. Furthermore, QVA149 was remarkably more effective than placebo in decreasing both respiratory symptoms and the use of as-needed short-acting rescue bronchodilators [29]. The main aim of the SPARK study, performed in 362 centers located in 27 countries, was to evaluate the efficacy of QVA149, by comparing it over 64 weeks to either
glycopyrronium or tiotropium, with regard to prevention of COPD exacerbations [30]. In particular, 2,224 patients with severe or very severe COPD were enrolled, presenting a post-bronchodilator FEV₁ less than 50% of predicted, who had experienced at least one exacerbation in the year prior to enrollment. Therefore, following a double-blind, randomized design, 741 subjects were assigned to treatment with QVA149, 741 to monotherapy with glycopyrronium (50 mcg daily through Breezhaler device) and 742 to monotherapy with tiotropium (18 mcg daily via HandiHaler device). The results showed that QVA149 was able to significantly reduce the overall rate of all COPD exacerbations (mild, moderate and severe), at rates of 15% and 14% when compared to glycopyrronium and tiotropium, respectively [30]. Furthermore, a recent meta-analysis demonstrated that QVA149 can delay by 35% the onset of the next exacerbation [31]. With respect to glycopyrronium and tiotropium, the SPARK study also showed that QVA149 was able to induce a persistently and significantly greater increase in trough FEV1. Moreover, QVA149 was also more effective than either glycopyrronium or tiotropium in improving the global health status, as assessed by St. George’s Respiratory Questionnaire (SGRQ).

In the SHINE study, 2,144 patients with moderate-to-severe COPD (post-bronchodilator FEV₁ range: from 30% to 80% of predicted values) were randomly divided into five groups, each one receiving for 26 weeks, as once daily administration, one of the following treatments: 1) QVA149 (475 patients); 2) indacaterol 150 mcg (477 patients), 3) glycopyrronium 50 mcg (475 patients); 4) tiotropium 18 mcg (483 patients); 5) placebo (234 patients) [32]. With the exception of the group of patients undergoing treatment with tiotropium, who used the dry powder inhaler “HandiHaler”, all the other groups used Breezhaler as dry powder device. The majority of patients were male (75.4%), and had not experienced exacerbations during the year prior to enrollment (74.6%). Before starting the various treatments, there were no significant spirometric differences among the five groups. The results of the spirometries performed at week 26 of treatment showed that QVA149 induced, when compared to monotherapies with either indacaterol, glycopyrronium, tiotropium or placebo, significantly greater increases in trough FEV₁ and peak expiratory flow (PEF) [32]. With respect to placebo, tiotropium and glycopyrronium at week 12, as well as in comparison to tiotropium and placebo at week 26, QVA149 induced a greater improvement in dyspnea, assessed by transition dyspnea index (TDI). At the end of the study the overall health status, evaluated through the SGRQ score, resulted to be also significantly improved in the group treated with QVA149, when compared to the groups treated with either tiotropium or placebo. Furthermore, a significant decrease in the consumption of as needed short-acting bronchodilators, used as rescue medications, was detected in the group treated with QVA149, when compared to the other four groups.

The aim of the multicenter, double-blind, randomized ILLUMINATE trial, was to assess the effectiveness of QVA149 in comparison to the fixed LABA/ICS (inhaled corticosteroid) combination consisting of salmeterol 50 mcg plus fluticasone propionate 500 mcg (SFC), delivered twice daily via Diskus dry powder inhaler [33]. In particular, this study lasted 26 weeks and included 523 current or ex-smokers with moderate to severe COPD (age ≥ 40 years), who had no disease exacerbation during the year prior to their enrollment. Airflow limitation was characterized by a post-bronchodilator FEV₁ ranging from 40% to 80% of the predicted values. The results of this study showed that QVA149 induced, when compared to SFC, a significantly higher FEV₁ increase, already detectable during the first study day, as well as at the 12th and 26th week [33]. QVA149 was significantly more effective than SFC in decreasing the use of as needed short-acting bronchodilators, as well as in improving dyspnea, assessed by TDI. No significant difference was found between the two treatments with regard to health status, assessed by SGRQ [33]. A logical extension of this study is the ongoing FLAME trial, which is investigating the effects of QVA149, compared with SFC, on COPD exacerbation rates [34]. LANTERN is a further ongoing study which is evaluating the efficacy of QVA149 versus SFC over 26 weeks, in COPD patients from Argentina, Brazil, Chile, China and Taiwan [35].

The BRIGHT study investigated the effects of QVA149 on exercise tolerance, lung volumes, and dynamic hyperinflation in patients with moderate-to-severe COPD over 3 weeks [36]. This trial showed that exercise endurance time was significantly increased by QVA149 when compared to placebo, with an improvement pattern similar to that induced by tiotropium. Moreover, in comparison to placebo and tiotropium, QVA149 elicited significantly greater decreases in lung hyperinflation both at rest and during exercise [36]. Of remarkable clinical relevance are also the results of the BLAZE study, a multicentre, blinded, double-dummy, crossover trial, which enrolled 247 patients with moderate-to-severe COPD who were randomly assigned to receive once-daily QVA149, placebo or tiotropium [37]. Improvements in dyspnea were assessed via the self-administered computerized (SAC) version of TDI after 6 weeks. At this time, the SAC TDI total score resulted significantly higher when patients used QVA149, as compared with both placebo and tiotropium. Treatment with QVA149 was also associated, when compared to either placebo or tiotropium, with a significantly lower use of rescue medications [37].
Furthermore, several studies showed that, in addition to the excellent medium- and long-term clinical and functional effects induced by QVA149, the therapeutic profile of this drug co-formulation is also characterized by a very fast onset of bronchodilation, already detectable at 5 min post-dose on day one [32,33,37,38]. This feature of QVA149 is very important in that it makes possible to provide an immediate symptom relief, especially in the morning soon after awakening. Overall, the efficacy of QVA149 is very similar to that achievable with the concurrent administration of its monocomponents indacaterol and glycopyrronium [39]. Indeed, the BEACON trial, which enrolled 193 patients randomized to receive either QVA149 or indacaterol plus glycopyrronium as concurrent, independent inhalations, documented that both treatment groups experienced similar FEV₁ improvements, as well as analogous reductions in symptom scores and rescue medication use [39].

Safety and tolerability profile
According to many studies, QVA149 is well tolerated and is characterized by a favourable safety profile with respect to its individual monocomponents [26]. A pooled analysis of 6-month safety data extrapolated from SHINE, ILLUMINATE, ENLIGHTEN and ARISE (a safety study carried out in Japanese patients) trials, showed that the proportion of subjects treated with QVA149 who experienced cardio- and cerebro-vascular events was very similar to that detected in COPD patients treated with tiotropium (1.8% and 1.7%, respectively), and lower than that observed in patients receiving treatment with placebo (2.6%) [40]. The proportion of patients who reported one or more cardio- and cerebro-vascular serious adverse events in the QVA149 group was 0.6%, comparable to or slightly lower than those reported by patients undergoing other active treatments [40]. Additionally, no significant differences among QVA149 and the other treatment groups were detected with regard to the incidence of unwanted side effects in SPARK, BRIGHT and BLAZE studies [30,36,37].

In general, once-daily dosing of QVA149 is well accepted by COPD patients [5]. Moreover, the combined use of indacaterol and glycopyrronium is further favoured by the inhalation device used. In fact, the dry powder inhaler Breezhaler is characterized by a low airflow resistance, that thus allows the activation of the device with an affordable inspiratory effort [41]. This feature is very important because Breezhaler can thus be easily used even by patients with the most severe forms of COPD, which of course include the main candidates for the dual, LABA/LAMA, combined therapy. In fact, the magnitude of the peak inspiratory flow (PIF) decreases gradually as disease severity increases. However, since Breezhaler can be activated by a relatively low inspiratory flow, its use is markedly suitable for almost all patients with COPD, also including those characterized by the most severe degrees of respiratory functional impairment. In addition, Breezhaler has other remarkable advantages, especially related to auditory, gustatory and visual perceptions, that make it possible for the patient to be sure of having properly inhaled drug medications. Indeed, the release of a drug fixed dose by Breezhaler is associated with an audible hum in the inhalation chamber, the sensation of a sweet taste due to the presence of lactose, and the appreciation of powder emptying due to the transparency of the capsule inserted into the inhaler. All these features of Breezhaler, associated with the advantage of once daily administration, guarantee a high degree of compliance by COPD patients, with a consequent considerable increase in the adherence to prescribed inhaled therapy [42].

Conclusions
Based on the above study results, it can thus be argued that a dual bronchodilating treatment, performed through the use of an inhaled pharmaceutical formulation capable of simultaneously delivering indacaterol and glycopyrronium, is characterized by a greater therapeutic effectiveness when compared to monotherapies consisting of each drug administered alone. Therefore, this experimental evidence confirms the pharmacologic rationale underlying the synergistic potentiation of the bronchodilating actions exerted by different drugs such as LABA and LAMA, which act via distinct mechanisms of action. Such an enhanced therapeutic efficacy can be achieved without increasing the incidence of adverse events. This suggests that the co-formulation of indacaterol and glycopyrronium can be usefully utilized to optimize and maximize bronchodilation in many COPD patients, who do not experience an adequate airflow increase by using a single bronchodilator. This results in greater improvements in subjective symptoms, lung function and overall quality of life. In addition, the enhancement of airway stabilization and the long-term persistence of airway patency (pharmacologic “airway stenting”), associated with a more effective prevention of COPD exacerbations, are likely to slow the rate of disease progression, as well as to concomitantly reduce mortality.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
All authors contributed to write this review and approved the final manuscript.

Acknowledgements
We thank all the members of the medical staff of the Respiratory Unit of the University “Magna Graecia” of Catanzaro (Italy), who constantly contribute to collect relevant clinical and functional data referring to patients with COPD.
References

1. Cazzola M, Page CV, Cazzola M: Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011, 32:405–506.

2. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Rosin R: Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347–383.

3. Matera MG, Page CV, Cazzola M: NVA237, a long-acting muscarinic antagonist, as 3.1.2 agonist of tiotropium and investigational drugs. Eur Respir J 2010, 36:1498–1499.

4. Barnes PJ: Direct-acting combination therapies. Eur Respir J 2013, 42:1484–1494.

5. Cazzola M, Proietto A, Matera MG: Indacaterol and salmeterol: do they influence their pharmacological stability? Chest 2003, 123:566–572.

6. Cazzola M, Page CV, Rogliani P, Matera MG: β₂-Agonist therapy in lung disease. Am J Respir Crit Care Med 2013, 187:690–696.

7. Chapman KR, Remillard SL, Dogra A, Owen R, Lassen C, Kramer B, on behalf of the INDORSE Study Investigators: Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011, 140:68–75.

8. Vogelmeier C, Banerji D: NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Thor Adv Respir Dis 2011, 1:613–673.

9. Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, Lu Y, Banerji D: Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012, 40:1106–1114.

10. Barnes PJ: Biochemical basis of asthma therapy. J Biol Chem 2011, 286:32899–32905.

11. Cazzola M, Page CV, Rogliani P, Matera MG: β₂-Agonist therapy in lung disease. Am J Respir Crit Care Med 2013, 187:690–696.

12. Cazzola M, Proietto A, Matera MG: Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today 2010, 46:139–150.

13. Lombardi D, Cuenoud B, Kramer SD: Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009, 38:533–547.

14. Casarosa P, Bogyo M, Germeyer S, Schnapp A, Gantert F, Pieper M: Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 2009, 330:606–688.

15. Sykes DA, Dowling MR, Leighton-Davies J, Kent TC, Fawcett L, Renard E, Triffitt A, Charlton SJ: The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J Pharmacol Exp Ther 2012, 343:320–328.

16. Roffé AF, Elzinga CR, Zaagsma J: Muscarinic M₃ receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol 1993, 8:47–51.

17. Caulson PR, Fryer AD: Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther 2003, 99:223–69.

18. Harvey RD: Muscarinic receptor agonists and antagonists: effects on cardiovascular function. Handb Exp Pharmacol 2012, 208:289–316.

19. Pelaia G, Renda T, Gallelli L, Vatrella A, Busceti MT, Agati S, Caputi M, Cazzola M, Maselli R, Manisco SA: Molecular mechanisms underlying airway smooth muscle contraction and proliferation: implications for asthma. Respir Med 2008, 102:1173–1181.

20. D’Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011, 12:516.

21. Holden NS, Bell MJ, Rider CF, King EM, Gaunt DD, Leigh R, Johnson M, Sidovernik DP, Hoxier SP, Giembycz MA, Newton R: β₂-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids. Proc Natl Acad Sci U S A 2011, 108:19713–19718.

22. Houslay MD: ‘Crosstalk’: a pivotal role for protein kinase C in modulating relationships between signal transduction pathways. Eur J Biochem 1991, 195:9–27.

23. Meurs H, Dekkers BGI, Maarsingh H, Halayko AJ, Zaaqma J, Gosens R: Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther 2013, 26:145–155.

24. Chuang TT, Iacovelli L, Sallese M, De BA: G protein-coupled receptors: heterologous regulation of homologous desensitization and its implications. Trends Pharmacol Sci 1996, 17:416–421.

25. Penn RB: Embracing emerging paradigms of G-protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. Naunyn Schmiedebergs Arch Pharmacol 2008, 378:149–169.

26. Bateman ED, Mahler DA, Vogelmeier CF, Wedzicha JA, Patalano F, Banerji D: Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med 2014, 8:357–379.

27. European Medicine Agency: Ulbroca Breatheal. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002679/human_med_001691.jsp (accessed October 15, 2014).

28. Health Canada. Available from Health Canada: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/prodpharm/applic-demande/regist/regx Innov_drd-end.pdf (accessed October 15, 2014).

29. Dahl R, Chuang TT, Iacovelli L, Sallese M, De BA: Dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir Med 2013, 107:1558–1567.

30. Wedzicha JA, Decramer M, Ficker JH, Newhofer DE, Sandstrom T, Fowler Taylor A, D’Andrea P, Arsacat C, Chen H, Banerji D: Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrrolate and tiotropium (SPARK: a randomised, double-blind, parallel-group study. Lancet Respir Med 2013, 1:199–209.

31. Banerji D, Fedele MJ, Chen H, Kim HJ: Dual bronchodilation with QVA149 reduces COPD exacerbations: results from the ignite program. Respirpol 2013, 18(Suppl 1):41–81.

32. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Herley M, Banerji D: Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013, 42:1484–1494.

33. Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D’Andrea P, Chen H, Banerji D: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013, 1:51–60.

34. Clinical Trials.gov Identifier: NCT01782326. Available from: http://clinicaltrials. gov/show/NCT01782326.

35. Clinical Trials.gov Identifier: NCT01709093. Available from: http://clinicaltrials.g ov/show/NCT01709093.

36. Beek K-M, Kom S, Beier J, Jadad D, Heneley M, D’Andrea P, Banerji D: Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med 2014, 108:584–592.

37. Mahler DA, Decramer M, D’Urzo A, Worth H, White T, Alagappan VK, Chen H, Gallagher N, Kulch K, Banerji D: Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 2014, 43:1599–1609.

38. Dahl R, Gallagher N, Green Y, Byant H, Chen H, D’Andrea P, Alagappan VK, Banerji D: QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD. Eur Respir J 2013, 42(Suppl 5):3385.

39. Dahl R, Jadad D, Alagappan VK, Chen H, Banerji D: Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrrolate: the BEACON study. Int J COPD 2013, 8:501–508.

40. Ferguson G, Barnes N, Mehta R: Cardio- and cerebro-vascular safety profile of QVA149 in patients with COPD: a pooled analysis [Abstract]. Am J Respir Crit Care Med 2013, 187(1):A1488.
41. Pavkov R, Mueller S, Fiebich K, Singh D, Stowasser F, Pignatelli G, Walter B, Ziegler D, Dalvi M, Dederichs J, Rietveld I. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. *Curr Med Res Opin* 2010, 26:2527–2533.

42. Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, Sikkier-Ortiz J, Gardner DD, Wilkins RL. Medication adherence issues in patients treated for COPD. *Int J COPD* 2008, 3:371–384.